Carlton Hofferkamp Jenks Wealth Management buys $1,737,832 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Carlton Hofferkamp Jenks Wealth Management scooped up 65 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 18, 2016. The investment management firm now holds a total of 29,560 shares of Merck & Co. which is valued at $1,737,832.Merck & Co. makes up approximately 1.33% of Carlton Hofferkamp Jenks Wealth Management’s portfolio.

Other Hedge Funds, Including , Vigilant Capital Management boosted its stake in MRK in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 1,496 shares of Merck & Co. which is valued at $87,950. Merck & Co. makes up approx 0.02% of Vigilant Capital Management’s portfolio.Davenport Co boosted its stake in MRK in the latest quarter, The investment management firm added 9,414 additional shares and now holds a total of 1,651,820 shares of Merck & Co. which is valued at $98,365,881. Merck & Co. makes up approx 1.46% of Davenport Co’s portfolio. Keel Point added MRK to its portfolio by purchasing 3,544 company shares during the most recent quarter which is valued at $211,045. Merck & Co. makes up approx 0.09% of Keel Point’s portfolio.Summit Financial Wealth Advisors boosted its stake in MRK in the latest quarter, The investment management firm added 4,063 additional shares and now holds a total of 11,838 shares of Merck & Co. which is valued at $702,585. Merck & Co. makes up approx 0.29% of Summit Financial Wealth Advisors’s portfolio.

Merck & Co. opened for trading at $59 and hit $59.119 on the upside on Wednesday, eventually ending the session at $58.79, with a gain of 0.22% or 0.13 points. The heightened volatility saw the trading volume jump to 64,76,048 shares. Company has a market cap of $162,732 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.